Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of Pfenex Expression Technology(TM)

San Diego/Ingelheim (OTS) - Pfenex Inc., an industry leader in
protein expression through the Pfenex Expression Technology(TM)
platform and Boehringer Ingelheim International GmbH, a leading
pharmaceutical company and global leader in biopharmaceutical
contract development and manufacture, announced today that they have
entered into a strategic agreement. It provides Boehringer Ingelheim
with non-exclusive access to the Pfenex Expression Technology. Under
the terms of the multi-year agreement, Pfenex Inc. will engineer
production strains and processes for Boehringer Ingelheim's
proprietary molecules, and molecules from Boehringer Ingelheim's
contract manufacturing customers. This collaboration provides
Boehringer Ingelheim and their customers with access to an
industry-leading expression platform to enable preclinical and
clinical development to progress much more quickly and efficiently.

"We are very pleased to have established this agreement with
Boehringer Ingelheim," said Dr Bertrand Liang, CEO of Pfenex Inc.
"This partnership combines a cutting edge expression technology with
the leading innovative pharmaceutical company and contract services
provider, facilitating the speed and reliability with which important
new drugs can be brought to patients."

"This collaboration extends our contract manufacturing service
portfolio by an additional high expression system and is a further
step in our strategy to offer customers leading technologies", stated
Simon Sturge, Corporate SVP of the Biopharmaceuticals Division at
Boehringer Ingelheim. "The Pfenex Expression Technology(TM) delivers
excellent expression rates, and we are looking forward to realizing
customer projects with this technology."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique
and powerful Pfenex Expression Technology(TM) platform based on the
microorganism, Pseudomonas fluorescens, for the production of
research proteins, reagent proteins, biosimilars and innovator
biopharmaceuticals. For more information please visit www.pfenex.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 142 affiliates in 50 countries and more than
41,500 employees. Since it was founded in 1885, the family-owned
company has been committed for 125 years to researching, developing,
manufacturing and marketing novel products of high therapeutic value
for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world's leading
companies for contract development and manufacture of
biopharmaceuticals. All types of services from mammalian cell line or
microbial strain development to final drug production can be
delivered within a one-stop-shop concept. Boehringer Ingelheim
delivers services for pre-clinical development up to global market
supply with a strong commitment to its customers at its manufacturing
facilities for mammalian cell culture and microbial fermentation.
Boehringer Ingelheim has brought 18 molecules to market and has many
years of experience in multiple molecule classes such as monoclonal
antibodies, recombinant proteins, interferons, enzymes, fusion
molecules and plasmid DNA. Furthermore, high-titer platform
technologies for new antibody mimetic formats such as scaffold
proteins and antibody fragments are available for the manufacture of
customer products.

Rückfragehinweis:

For more information contact:
   mailto:[email protected] or 
   www.biopharma-cmo.com
   
   Media Contact:
   Pfenex Inc. 
   Patrick Lucy
   Pfenex Inc.
   Vice President, Business Development
   Tel.: 978-887-4971
   mailto:[email protected]
   
   Boehringer Ingelheim: 
   Communications
   Vienna/Austria
   
   Inge Homolka
   Tel.: +43-1-80105-2230
   mailto:[email protected]
   
   Monika Primenz
   Tel.: +43-1-80105-2742
   mailto:[email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | IMP

print